For the second time in just over six months, there’s a newcomer in a next-generation class of breast cancer-fighters. Thursday, U.S. regulators greenlighted Eli Lilly’s Verzenio, better known as abemaciclib. The drug will join a pair of HR-postive, HER2-negative meds in Pfizer’s Ibrance and Novartis’ Kisqali, the latter of which won its own FDA approval […]